[go: up one dir, main page]

US20070021487A1 - Azabicyclo derivatives as muscarinic receptor antagonists - Google Patents

Azabicyclo derivatives as muscarinic receptor antagonists Download PDF

Info

Publication number
US20070021487A1
US20070021487A1 US10/552,503 US55250304A US2007021487A1 US 20070021487 A1 US20070021487 A1 US 20070021487A1 US 55250304 A US55250304 A US 55250304A US 2007021487 A1 US2007021487 A1 US 2007021487A1
Authority
US
United States
Prior art keywords
compound
methyl
formula
azabicyclo
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/552,503
Other languages
English (en)
Inventor
Mohammad Salman
Naresh Kumar
Pakala Sarma
Sankaranarayanan Dharmarajan
Anita Chugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/001367 external-priority patent/WO2004005252A1/fr
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Assigned to RANBAXY LABORATORIES LIMITED reassignment RANBAXY LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHUGH, ANITA, DHARMARAJAN, SANKARANARAYANAN, KUMAR, NARESH, SARMA, PAKALA KUMARA SAVITHRU, SALMAN, MOHAMMAD
Publication of US20070021487A1 publication Critical patent/US20070021487A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
  • the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0]hexanes, as well as pharmaceutical compositions containing such compounds and methods of treating diseases mediated through muscarinic receptors.
  • Muscarinic receptors as members of the G Protein Coupled Receptors are composed of a family of 5 receptor sub-types (M 1 , M 2 , M 3 , M 4 and M 5 ) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented.
  • the M 1 subtype is located primarily in neuronal tissues such as cerebral cortex and autonomic ganglia
  • the M 2 subtype is present mainly in the heart where it mediates cholinergically induced bradycardia
  • the M 3 subtype is located predominantly on smooth muscle and salivary glands ( Nature, 323, p. 411 (1986); Science, 237, p. 527 (1987)).
  • Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, making it difficult to assign specific functions to the individual receptors.
  • classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc.
  • WO 01/42213 describes 2-biphenyl-4-piperidinyl ureas.
  • WO 01/42212 describes carbamate derivatives.
  • WO 01/90081 describes amino alkyl lactam.
  • WO 02/53564 describes novel quinuclidine derivatives.
  • WO 02/00652 describes carbamates derived from arylalkyl amines.
  • WO 02/06241 describes 1,2,3,5-tetrahydrobenzo(c)azepin-4-one derivatives.
  • azabicyclo derivatives including, for example, 6-substituted azabicyclo[3.1.0]hexanes, 2,6- and 4,6-disubstituted derivatives and 2,4,6-trisubstituted derivatives are provided as muscarinic receptor antagonists which can be useful as safe and effective therapeutic or prophylactic agents for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems. Also provided are processes for synthesizing such compounds.
  • compositions containing such compounds are provided together with acceptable carriers, excipients or diluents which can be useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
  • the enantiomers, diastereomers, N-oxides, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates of these compounds as well as metabolites having the same type of activity are also provided, as well as pharmaceutical compositions comprising the compounds, their metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
  • compounds having the structure of Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, metabolites, wherein R 1 and R 2 are independently selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl or optionally substituted phenyl wherein optional substituent(s) can be selected from C 1 -C 3 alkyl, C 1-93 alkoxy or halogen; Z can represent oxygen or NR 3 wherein R 3 represents hydrogen or C 1 -C 3 alkyl.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors includes administration of at least one compound having the structure of Formula I.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder associated with muscarinic receptors comprising administering to a patient in need thereof, an effective amount of a muscarinic receptor antagonist compound as described above.
  • a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like; urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc.; and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors.
  • a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like
  • urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc.
  • gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors
  • the compounds described herein exhibit significant potency in terms of their activity, as determined by in vitro receptor binding and functional assays and in vivo experiments using anaesthetized rabbits.
  • the compounds that were found active in vitro were tested in vivo.
  • Some of the compounds are potent muscarinic receptor antagonists with high affinity towards M 3 receptors. Therefore, pharmaceutical compositions for the possible treatment for the disease or disorders associated with muscarinic receptors are provided.
  • the compounds can be administered orally or parenterally.
  • the compounds of Formula V may be prepared, for example, by the reaction sequence as shown in Scheme I.
  • the preparation comprises reacting a compound of Formula II with a compound of Formula III, wherein
  • R 1 and R 2 are independently selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl or optionally substituted phenyl wherein optional substituent(s) is/are selected from C 1 -C 3 alkyl, C 1 -C 3 alkoxy or halogen;
  • R 3 represents hydrogen or C 1 -C 3 alkyl
  • P is any protecting group for an amino group, for example, benzyl or t-butyloxy carbonyl groups.
  • the reaction between a compound of Formula II and a compound of Formula III can take place in the presence of N-methylmorpholine and 1-hydroxybenzotriazole and a condensing agent (for example, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC), 1,3-dicyclohexylcarbodiimide (DCC) or 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU)), in a solvent (such as N,N-dimethylformamide, dimethylsulfoxide, toluene, xylene or chloroform, at temperatures ranging from about 0 to about 140° C.), to give a protected compound of Formula IV which on deprotection in the presence of a deprotecting agent (for example, palladium on carbon and hydrogen, ammonium formate and palladium on carbon, trifluoroacetic acid (TFA) or hydrochloric acid) in an organic solvent (for
  • the compounds of Formula VIII may be prepared for example, by the reaction sequence as shown in Scheme II.
  • the preparation comprises reacting a compound of Formula II with a compound of Formula VI, wherein
  • R 1 and R 2 are independently selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl or optionally substituted phenyl wherein optional substituent(s) is/are selected from C 1 -C 3 alkyl C 1 -C 3 alkoxy or halogen;
  • R′ is any protecting group for hydroxy group, for example, p-toluene sulfonyl or methane sulfonyl and
  • P is any protecting group for an amino group, for example, benzyl or t-butyloxy carbonyl groups.
  • the reaction between a compound of Formula II and a compound of Formula VI can take place in the presence of a condensing agent (for example, 1,8-diazabicyclo[5.4.0]undecan-7-ene (DBU) or 1,4-diazabicyclo[2.2.2]octane (DABCO), in a solvent (such as benzene, toluene or xylene, at temperatures ranging from about 0 to about 140° C.), to give a protected compound of Formula VII which on deprotection in the presence of a deprotecting agent (for example, palladium on carbon and hydrogen or ammonium formate and palladium on carbon) in an organic solvent (for example, methanol or ethanol, at temperatures ranging from about 10 to about 50° C.) gives an unprotected compound of Formula VIII.
  • a condensing agent for example, 1,8-diazabicyclo[5.4.0]undecan-7-ene (DBU) or 1,4-diazabicy
  • Suitable salts of the compounds represented by the Formula I were prepared so as to solubilize the compound in aqueous medium for biological evaluations, as well as to be compatible with various dosage formulations and also to aid in the bioavailability of the compounds.
  • examples of such salts include pharmacologically acceptable salts such as inorganic acid salts (for example, hydrochloride, hydrobromide, sulphate, nitrate and phosphate), organic acid salts (for example, acetate, tartarate, citrate, fumarate, maleate, tolounesulphonate and methanesulphonate).
  • carboxyl groups When carboxyl groups are included in the Formula I as substituents, they may be present in the form of an alkaline or alkali metal salt (for example, sodium, potassium, calcium, magnesium, and the like). These salts may be prepared by various techniques, such as treating the compound with an equivalent amount of inorganic or organic, acid or base in a suitable solvent.
  • alkaline or alkali metal salt for example, sodium, potassium, calcium, magnesium, and the like.
  • the compounds described herein may be administered to an animal for treatment orally, or by a parenteral route.
  • the pharmaceutical compositions described herein can be produced and administered in dosage units, each unit containing a certain amount of at least one compound described herein and/or at least one physiologically acceptable addition salt thereof.
  • the dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity.
  • the compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient.
  • the compounds described herein can be produced and formulated as their enantiomers, diastereomers, N-Oxides, polymorphs, solvates and pharmaceutically acceptable salts, as well as metabolites having the same type of activity.
  • Pharmaceutical compositions comprising the molecules of Formula I or metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipient can also be produced.
  • Step a Synthesis of methane sulfonic acid 3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl ester
  • Step b Synthesis of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl) methylamine
  • Step c Synthesis of N-[(1 ⁇ ,5 ⁇ ,6 ⁇ )-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide
  • Step d Synthesis of N-[(1 ⁇ ,5 ⁇ ,6 ⁇ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide
  • the compound exhibited a melting point of 101-103° C.
  • Step a Synthesis of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl) amine
  • Step b Synthesis of N-[(1 ⁇ ,5 ⁇ ,6 ⁇ )-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide
  • Step c Synthesis of (2R,2S)-N-[(1 ⁇ ,5 ⁇ ,6 ⁇ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide
  • the hyflo bed was washed with methanol (75.0 mL), ethyl acetate (25.0 mL) and water (25.0 mL). The filterate was concentrated under vacuum. The residue was diluted with water and pH of the resulting solution was adjusted to (pH ⁇ 14) with 1N NaOH. Extracted with ethyl acetate (2 ⁇ 50 mL) and the ethyl acetate layer was washed with water and brine solution. Dried over anhydrous sodium sulphate and concentrated to give the title compound.
  • Step a Synthesis of [(1 ⁇ ,5 ⁇ ,6 ⁇ )-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenylacetic acid ester
  • Step b Synthesis of [(1 ⁇ ,5 ⁇ ,6 ⁇ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenylacetic acid ester
  • the hyflo bed was washed with methanol (75.0 mL), ethtl acetate (25.0 mL) and water (25.0 mL). The filterate was concentrated under vacuum. The residue was diluted with water and pH of the resulting solution was adjusted to (pH ⁇ 14) with 1N NaOH. Extracted with ethyl acetate (2 ⁇ 50 mL) and the ethyl acetate layer was washed with water and brine solution. Dried over anhydrous sodium sulphate and concentrated to give the title compound.
  • Radioligand Binding Assays The affinity of test compounds for M 2 and M 3 muscarinic receptor subtypes was determined by [ 3 H]-N-methylscopolamine binding studies, using rat heart and submandibular gland, respectively, as described by Moriya et al., ( Life Sci., 1999; 64(25): 2351-2358) with minor modifications as follows.
  • the membrane preparation was done with the following modifications: a low spin step of 500 g for 10 minutes at 4° C. was used; the buffer was 20 mM HEPES, 10 mM EDTA, at pH 7.4; the high speed spin was done at 40,000 g and the homogenate was passed through a filter gauge before any spinning.
  • the assay conditions were modified as follows: the assay volume was 250 ⁇ L; the incubation time was 3 hours; the PE concentration was 0.1%; the filtermat used was GF/B from Wallac; the scintillant used was Supermix from Wallac; the amount of scintillant was 500 ⁇ L/well; and the counter used was a 1450 microbeta PLUS, from Wallac.
  • Membrane preparation Submandibular glands and heart were isolated and placed in ice cold homogenising buffer (HEPES 20 mM, 10 mM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenised in 10 volumes of homogenising buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500 g for 10 min. The supernatant was subsequently centrifuged at 40,000 g for 20 min. The pellet thus obtained was resuspended in same volume of assay buffer (HEPES 20 mM, EDTA 5 mM, pH 7.4) and were stored at ⁇ 70° C. until the time of assay.
  • HEPES 20 mM, 10 mM EDTA, pH 7.4 ice cold homogenising buffer
  • Ligand binding assay The compounds were dissolved and diluted in DMSO. The membrane homogenates (150-250 ⁇ g protein) were incubated in 250 ⁇ l of assay buffer (HEPES 20 mM, pH 7.4) at 24-25° C. for 3 h. Non-specific binding was determined in the presence of 1 ⁇ M atropine. The incubation was terminated by vacuum filtration over GF/B fiber filters (Wallac). The filters were then washed with ice cold 50 mM Tris HCl buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC 50 and K d were estimated by using the non-linear curve fitting program using G Pad Prism software.
  • pK i ⁇ [log K i ].
  • Ki results of the compounds observed were in the range of 0.05 nM to 136 nM for M 3 receptor and 0.06 nM to 34.6 nM for M 2 receptor.
  • the bladder is cut into longitudinal strips (3 mm wide and 5-6 mm long) and mounted in 10 ml organ baths at 30° C., with one end connected to the base of the tissue holder and the other end connected to a polygraph through a force displacement transducer.
  • Each tissue is maintained at a constant basal tension of 2 g and allowed to equilibrate for 1 hour during which the PSS is changed every 15 min.
  • the stabilization of the tissue contractile response is assessed with 1 ⁇ mol/L of Carbachol consecutively, 2-3 times. Subsequently a cumulative concentration response curve to carbachol (10 ⁇ 9 mol/L to 3 ⁇ 10 ⁇ 5 mol/L) is obtained. After several washes, once the baseline is achieved, cumulative concentration response curve is obtained in presence of NCE (NCE added 20 min. prior to the second CRC).
  • the contractile results are expressed as % of control E max.
  • ED 50 values are calculated by fitting a non-linear regression curve (Graph Pad Prism).
  • the bladder was exposed through a midline laparotomy and both the ureters were identified, carefully separated and ligated.
  • the ureters were incised proximally to allow free flow of urine from the kidney to the exterior.
  • Bladder neck was gently held and the urethra was traced and separated from the adjoining tissues.
  • PE canula was introduced into the bladder and ligated.
  • the bladder was drained and subsequently filled with 15 ml of warm saline (37° C.).
  • the other end of the intravesical catheter was connected to the Grass model 7D polygraph through a Statham P10 EZ pressure transducer to monitor the bladder pressure. Care was taken to keep the exposed area moist and warm. A period of 30-60 min was allowed for stabilization of parameters subsequent to surgery. Salivation response was assessed by placing preweighed absorbent cotton gauze in the buccal cavity for 2 minutes after carbachol administration.
  • the change in bladder pressure, salivation and agonist induced bradycardia were expressed as % change from pretreatment control.
  • ID 50 values dose required to inhibit 50% of response
  • the ID 50 values for bladder pressure for compounds tested ranged from about 1.89 to about 4.2 ⁇ g/kg.
  • the ID 50 values for salivation for compounds tested ranged from about 3.7 to about 30.4 ⁇ g/kg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
US10/552,503 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists Abandoned US20070021487A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2003/001367 WO2004005252A1 (fr) 2002-07-08 2003-04-11 Derives azabicyclo utilises comme antagonistes des recepteur muscariniques
IBIB03/0167 2003-04-11
PCT/IB2004/000008 WO2004089900A1 (fr) 2003-04-11 2004-01-06 Derives azabicyclo utiles comme antagonistes du recepteur muscarinique

Publications (1)

Publication Number Publication Date
US20070021487A1 true US20070021487A1 (en) 2007-01-25

Family

ID=33156169

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/552,503 Abandoned US20070021487A1 (en) 2003-04-11 2004-01-06 Azabicyclo derivatives as muscarinic receptor antagonists
US10/552,455 Expired - Fee Related US7446123B2 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/552,455 Expired - Fee Related US7446123B2 (en) 2003-04-11 2004-01-07 Azabicyclo derivatives as muscarinic receptor antagonists

Country Status (10)

Country Link
US (2) US20070021487A1 (fr)
EP (2) EP1626957A1 (fr)
JP (2) JP2006522787A (fr)
CN (2) CN100436414C (fr)
AU (2) AU2004228452A1 (fr)
BR (2) BRPI0409302A (fr)
CA (2) CA2522071A1 (fr)
EA (1) EA009387B1 (fr)
NZ (2) NZ542952A (fr)
WO (2) WO2004089900A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
CA2542279C (fr) * 2003-10-14 2011-08-09 Pfizer Products Inc. Derives [3.1.0] bicycliques utilises comme inhibiteurs des transporteurs de glycine
EP1828126A1 (fr) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Sels d'addition d'acide d'antagonistes du recepteur muscarinique
WO2006117754A1 (fr) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
WO2007007282A2 (fr) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
WO2007039884A1 (fr) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited Dérivés de 3 -azabicyclooctane en tant qu’antagonistes de récepteurs muscariniques
WO2007045979A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
US20090137623A1 (en) 2005-12-30 2009-05-28 Naresh Kumar Muscarinic receptor antagonists
AP2008004537A0 (en) 2005-12-30 2008-08-31 Ranbaxy Lab Ltd Muscarinic receptor antagonists
WO2008029349A2 (fr) * 2006-09-04 2008-03-13 Ranbaxy Laboratories Limited Antagonistes des récepteurs muscariniques
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP2621902B1 (fr) 2010-09-28 2017-04-12 Panacea Biotec Ltd Dérivés de 3-azabicyclo[3.1.0]hexane utiles pour le traitement de troubles du snc
CN103772379B (zh) * 2014-01-26 2016-06-15 寿光富康制药有限公司 一种曲司氯铵关键中间体的制备方法

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) * 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
US3176019A (en) * 1960-07-26 1965-03-30 Mead Johnson & Co Substituted aminobutynyl acetates
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5281601A (en) * 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
US5397800A (en) * 1990-09-13 1995-03-14 Pfizer Inc. Certain 1-azabicyclo[2.2.1]heptanes useful as muscarinic receptor antagonists
US5559269A (en) * 1992-11-06 1996-09-24 Pharmacia Ab 3,3-diphenylpropylamines, their use and preparation
US5948792A (en) * 1996-08-01 1999-09-07 Banyu Pharmaceutical Co., Ltd. Fluorine-containing 1,4-disubstituted piperidine derivatives
US6130232A (en) * 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
US6174900B1 (en) * 1995-06-26 2001-01-16 Ss Pharmaceutical Co., Ltd. Substituted piperidine derivative for treating urinary disturbance
US6313312B1 (en) * 1998-12-23 2001-11-06 Pfizer Inc 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
US20060247225A1 (en) * 2003-01-28 2006-11-02 Anita Mehta 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20060281805A1 (en) * 2003-04-09 2006-12-14 Anita Mehta Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20060287380A1 (en) * 2003-04-11 2006-12-21 Mohammad Salman Azabicyclo Derivatives as Muscarinic Receptor Antagonists
US20070010568A1 (en) * 2003-02-07 2007-01-11 Anita Mehta Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070135508A1 (en) * 2003-04-10 2007-06-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7288562B2 (en) * 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
US7399779B2 (en) * 2002-07-08 2008-07-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
RU2049777C1 (ru) 1989-08-16 1995-12-10 Пфайзер Инк. Азабицикло-хинолон-карбоновые кислоты или их фармацевтически приемлемые кислотно-аддитивные соли и промежуточные продукты для их получения
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
FR2659323B1 (fr) 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
EP0613232B1 (fr) 1993-02-24 1997-04-23 Siemens Aktiengesellschaft Convertisseur à récupération avec un interrupteur à semi-conducteur de base tenue en tension
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0823423B1 (fr) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. Derives disubstitues en position 1,4 de piperidine
WO1997045414A1 (fr) 1996-05-31 1997-12-04 Banyu Pharmaceutical Co., Ltd. Derives de piperidine a disubstitution en positions 1,4
EP0843141B1 (fr) * 1996-11-19 1998-06-03 GEA Wärme- und Umwelttechnik GmbH Dispositif de chargement de charbon pour une installation de séchage de lignite
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
CA2291778A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
JP2003516390A (ja) 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
PL204753B1 (pl) 2000-05-25 2010-02-26 Hoffmann La Roche Podstawiony 1-aminoalkilolaktam , zawierający go środek farmaceutyczny, sposób wytwarzania podstawionego 1-aminoalkilolaktamu i jego zastosowanie
MXPA02011417A (es) 2000-05-25 2003-04-25 Hoffmann La Roche 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
WO2002006241A1 (fr) 2000-06-14 2002-01-24 Muscagen Limited Derives de 1, 2, 3, 5 -tetrahydrobenzo`c!azepine-4-one presentant une activite antagoniste muscarinique
EA005520B1 (ru) 2000-06-27 2005-04-28 Лабораториос С.А.Л.В.А.Т.,С.А. Карбаматы, полученные из арилалкиламинов
CA2415468A1 (fr) * 2000-07-11 2003-01-10 Yoshio Ogino Derives d'ester
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
NZ526674A (en) * 2000-12-28 2005-03-24 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
WO2002083863A2 (fr) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole et autres ligands heterocycliques pour recepteurs et transporteurs mammaliens de serotonine, de dopamine et de la muscarine, et methodes d'utilisation correspondantes
JP2005512974A (ja) 2001-10-17 2005-05-12 ユ セ ベ ソシエテ アノニム キヌクリジン誘導体、その調製方法、及びｍ２及び／又はｍ３ムスカリン受容体阻害剤としてのその使用
BR0214649A (pt) 2001-12-03 2004-11-03 Hoffmann La Roche Derivados de aminotetralina como antagonistas do receptor muscarìnico
BR0214674A (pt) 2001-12-03 2004-10-19 Hoffmann La Roche Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
WO2004014363A1 (fr) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
EP1572648B1 (fr) 2002-12-10 2008-07-09 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo (3.1.0 hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
ATE386738T1 (de) 2002-12-23 2008-03-15 Ranbaxy Lab Ltd Flavaxat-derivate als muscarin-rezeptor antagonisten
EP1583741A1 (fr) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
EP1590345A1 (fr) 2002-12-23 2005-11-02 Ranbaxy Laboratories, Ltd. Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques
DE60313898T2 (de) 2003-04-10 2008-01-17 Ranbaxy Laboratories, Ltd. Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
FR2855805B1 (fr) 2003-06-06 2005-08-05 Vallourec Vitry Element de structure pour vehicule, capable d'un meilleur comportement aux chocs
EP1746998A1 (fr) 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Therapie combinee destinee a reduire les symptomes des voies urinaires
US20090176856A1 (en) 2004-09-27 2009-07-09 Anita Mehta Muscarinic receptor antagonists
EP1828126A1 (fr) 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Sels d'addition d'acide d'antagonistes du recepteur muscarinique

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) * 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
US3176019A (en) * 1960-07-26 1965-03-30 Mead Johnson & Co Substituted aminobutynyl acetates
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5281601A (en) * 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
US5397800A (en) * 1990-09-13 1995-03-14 Pfizer Inc. Certain 1-azabicyclo[2.2.1]heptanes useful as muscarinic receptor antagonists
US5559269A (en) * 1992-11-06 1996-09-24 Pharmacia Ab 3,3-diphenylpropylamines, their use and preparation
US6174900B1 (en) * 1995-06-26 2001-01-16 Ss Pharmaceutical Co., Ltd. Substituted piperidine derivative for treating urinary disturbance
US6130232A (en) * 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
US5948792A (en) * 1996-08-01 1999-09-07 Banyu Pharmaceutical Co., Ltd. Fluorine-containing 1,4-disubstituted piperidine derivatives
US6313312B1 (en) * 1998-12-23 2001-11-06 Pfizer Inc 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
US7399779B2 (en) * 2002-07-08 2008-07-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
US7288562B2 (en) * 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
US20060247225A1 (en) * 2003-01-28 2006-11-02 Anita Mehta 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070010568A1 (en) * 2003-02-07 2007-01-11 Anita Mehta Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20060281805A1 (en) * 2003-04-09 2006-12-14 Anita Mehta Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070135508A1 (en) * 2003-04-10 2007-06-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20060287380A1 (en) * 2003-04-11 2006-12-21 Mohammad Salman Azabicyclo Derivatives as Muscarinic Receptor Antagonists
US7446123B2 (en) * 2003-04-11 2008-11-04 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
WO2004089364A1 (fr) 2004-10-21
EP1620087A1 (fr) 2006-02-01
NZ542952A (en) 2008-11-28
EA009387B1 (ru) 2007-12-28
JP2006522787A (ja) 2006-10-05
NZ542951A (en) 2008-11-28
AU2004228452A2 (en) 2004-10-21
AU2004228760A1 (en) 2004-10-21
US20060287380A1 (en) 2006-12-21
US7446123B2 (en) 2008-11-04
CA2521989A1 (fr) 2004-10-21
AU2004228452A1 (en) 2004-10-21
CN1794985A (zh) 2006-06-28
JP2006522788A (ja) 2006-10-05
EP1626957A1 (fr) 2006-02-22
BRPI0409302A (pt) 2006-04-11
WO2004089900A1 (fr) 2004-10-21
BRPI0409308A (pt) 2006-05-02
CN100436414C (zh) 2008-11-26
CA2522071A1 (fr) 2004-10-21
EA200501593A1 (ru) 2006-06-30
CN1795176A (zh) 2006-06-28

Similar Documents

Publication Publication Date Title
US7399779B2 (en) 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
US7265147B2 (en) 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US20070021487A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
US7592359B2 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070010568A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20060281805A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7465751B2 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
WO2004056810A1 (fr) Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques
US7560479B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20100035954A1 (en) Acid addition salts of muscarinic receptor antagonists
US20080319002A1 (en) Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
HK1082728B (en) Azabicyclo derivatives as muscarinic receptor antagonists
HK1079783B (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
KR20060014373A (ko) 무스카린 수용체 길항제로서의 치환된 아자비시클로 헥산유도체

Legal Events

Date Code Title Description
AS Assignment

Owner name: RANBAXY LABORATORIES LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SALMAN, MOHAMMAD;KUMAR, NARESH;SARMA, PAKALA KUMARA SAVITHRU;AND OTHERS;REEL/FRAME:017742/0702;SIGNING DATES FROM 20040108 TO 20051111

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE